Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme
Authors
Lebrett, M. B.Balata, H.
Evison, M.
Colligan, D.
Duerden, R.
Elton, P.
Greaves, M.
Howells, J.
Irion, K.
Karunaratne, D.
Lyons, J.
Mellor, S.
Myerscough, A.
Newton, T.
Sharman, A.
Smith, E.
Taylor, Benjamin
Taylor, S.
Walsham, A.
Whittaker, J.
Barber, P. V.
Tonge, J.
Robbins, H. A.
Booton, R.
Crosbie, P. A. J.
Affiliation
Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, ManchesterIssue Date
2020
Metadata
Show full item recordAbstract
Introduction: Low-dose CT (LDCT) screening of high-risk smokers reduces lung cancer (LC) specific mortality. Determining screening eligibility using individualised risk may improve screening effectiveness and reduce harm. Here, we compare the performance of two risk prediction models (PLCOM2012 and Liverpool Lung Project model (LLPv2)) and National Lung Screening Trial (NLST) eligibility criteria in a community-based screening programme. Methods: Ever-smokers aged 55-74, from deprived areas of Manchester, were invited to a Lung Health Check (LHC). Individuals at higher risk (PLCOM2012 score ?1.51%) were offered annual LDCT screening over two rounds. LLPv2 score was calculated but not used for screening selection; ?2.5% and ?5% thresholds were used for analysis. Results: PLCOM2012 ?1.51% selected 56% (n=1429) of LHC attendees for screening. LLPv2 ?2.5% also selected 56% (n=1430) whereas NLST (47%, n=1188) and LLPv2 ?5% (33%, n=826) selected fewer. Over two screening rounds 62 individuals were diagnosed with LC; representing 87% (n=62/71) of 6-year incidence predicted by mean PLCOM2012 score (5.0%). 26% (n=16/62) of individuals with LC were not eligible for screening using LLPv2 ?5%, 18% (n=11/62) with NLST criteria and 7% (n=5/62) with LLPv2 ?2.5%. NLST eligible Manchester attendees had 2.5 times the LC detection rate than NLST participants after two annual screens (?4.3% (n=51/1188) vs 1.7% (n=438/26 309); p<0.0001). Adverse measures of health, including airflow obstruction, respiratory symptoms and cardiovascular disease, were positively correlated with LC risk. Coronary artery calcification was predictive of LC (adjOR 2.50, 95% CI 1.11 to 5.64; p=0.028). Conclusion: Prospective comparisons of risk prediction tools are required to optimise screening selection in different settings. The PLCOM2012 model may underestimate risk in deprived UK populations; further research focused on model calibration is required. Keywords: lung cancer.Citation
Lebrett MB, Balata H, Evison M, Colligan D, Duerden R, Elton P, et al. Analysis of lung cancer risk model (PLCOM2012 and LLPv2) performance in a community-based lung cancer screening programme. Thorax. 2020;75(8):661-8.Journal
ThoraxDOI
10.1136/thoraxjnl-2020-214626PubMed ID
32631933Additional Links
https://dx.doi.org/10.1136/thoraxjnl-2020-214626Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/thoraxjnl-2020-214626
Scopus Count
Collections
Related articles
- Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD.
- Authors: Balata H, Harvey J, Barber PV, Colligan D, Duerden R, Elton P, Evison M, Greaves M, Howells J, Irion K, Karunaratne D, Mellor S, Newton T, Sawyer R, Sharman A, Smith E, Taylor B, Taylor S, Tonge J, Walsham A, Whittaker J, Vestbo J, Booton R, Crosbie PA
- Issue date: 2020 Aug
- Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
- Authors: Robbins HA, Alcala K, Swerdlow AJ, Schoemaker MJ, Wareham N, Travis RC, Crosbie PAJ, Callister M, Baldwin DR, Landy R, Johansson M
- Issue date: 2021 Jun
- Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
- Authors: Bartlett EC, Kemp SV, Ridge CA, Desai SR, Mirsadraee S, Morjaria JB, Shah PL, Popat S, Nicholson AG, Rice AJ, Jordan S, Begum S, Mani A, Derbyshire J, Morris K, Chen M, Peacock C, Addis J, Martins M, Kaye SB, Padley SPG, Devaraj A, West London Lung Screening Collaboration Group
- Issue date: 2020 Oct
- LDCT lung cancer screening in populations at different risk for lung cancer.
- Authors: Teles GBDS, Macedo ACS, Chate RC, Valente VAT, Funari MBG, Szarf G
- Issue date: 2020 Feb
- Risk perception and disease knowledge in attendees of a community-based lung cancer screening programme.
- Authors: Lebrett MB, Crosbie EJ, Yorke J, Hewitt K, Rowlands A, Badrick E, Gareth Evans D, Balata H, Booton R, Crosbie PAJ
- Issue date: 2022 Jun